Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
Company | Current Parent | Current Parent Industry | Primary Offense Type | Year | Agency | Penalty Amount |
---|---|---|---|---|---|---|
Clovis Oncology Inc. | Clovis Oncology | pharmaceuticals | investor protection violation | 2018 | SEC | $20,000,000 |
CAMBREX CHARLES CITY, INC. | Cambrex | pharmaceuticals | workplace safety or health violation | 2007 | OSHA | $6,375 |
CAMBREX CHARLES CITY, INC. | Cambrex | pharmaceuticals | workplace safety or health violation | 2018 | OSHA | $18,000 |
CAMBREX CHARLES CITY, INC | Cambrex | pharmaceuticals | hazardous waste violation | 2006 | EPA | $106,749 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | drug or medical equipment safety violation | 2007 | DOJ_ANTITRUST | $1,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2008 | EPA | $3,650,000 |
DuPont Pharmaceuticals Company | Bristol-Myers Squibb | pharmaceuticals | economic sanction violation | 2004 | OFAC | $6,600 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
Bristol-Myers Squibb Medical Imaging, Inc. | Bristol-Myers Squibb | pharmaceuticals | export control violation | 2004 | BIS | $16,200 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | fraud | 2005 | USAO | $300,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $55,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2008 | AL-AG | $11,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2010 | PA-AG | $27,600,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | MULTI-AG | $1,100,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | consumer protection violation | 2019 | WV-AG | $1,600,000 |
Bristol-Myers Squibb Company and Apothecon, Inc. | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2008 | ID-AG | $1,738,719 |
Celgene Corp. | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | kickbacks and bribery | 2016 | CA-INS | $30,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | environmental violation | 2011 | CT-ENV | $20,000 |
E R SQUIBB & SONS LLC | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2013 | NJ-ENV | $5,950 |
E.R. SQUIBB & SONS | Bristol-Myers Squibb | pharmaceuticals | environmental violation | 2009 | NJ-ENV | $10,000 |
BRISTOL MYERS SQUIBB CO | Bristol-Myers Squibb | pharmaceuticals | hazardous waste violation | 2005 | NJ-ENV | $12,000 |
BRISTOL-MYERS SQUIBB CO | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2003 | NJ-ENV | $28,000 |
BRISTOL-MYERS SQUIBB CO | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2001 | NJ-ENV | $6,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2021 | USAO | $75,000,000 |
Bristol Myers Squibb Co. | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2021 | MULTI-AG | $75,000,000 |
Abraxis Bioscience, Inc. | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2012 | CA-SCAQMD | $5,000 |
American BioScience Inc. | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | private lawsuit-federal | $815,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | private lawsuit-federal | $50,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $10,800,000 |
Bristol-Myers Squibb Co. | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $10,000,000 |
Bristol-Myers Squibb Co. | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $19,000,000 |
BRISTOL-MYERS SQUIBB | Bristol-Myers Squibb | pharmaceuticals | environmental violation | 2023 | MA-ENV | $11,615 |
BRISTOL - MYERS SQUIBB MEDICAL IMAGING INC | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2009 | EPA | $19,538 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2009 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,328,154 |
Bristol Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2008 | EPA | $66,770 |
Bristol Myers Squibb Manufacturing Company | Bristol-Myers Squibb | pharmaceuticals | hazardous waste violation | 2008 | EPA | $52,000 |
E.R. Squibb & Sons LLC | Bristol-Myers Squibb | pharmaceuticals | PCB violation | 2009 | EPA | $8,125 |
Celgene Corporation | Bristol-Myers Squibb | pharmaceuticals | PCB violation | 2013 | EPA | $6,035 |
BRISTOL-MYERS SQUIBB COMPANY | Bristol-Myers Squibb | pharmaceuticals | environmental violation | 2000 | EPA | $5,000 |
Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
Boehringer Ingelheim Pharmaceutical, Inc. | Boehringer Ingelheim | pharmaceuticals | labor relations violation | 2004 | NLRB | $50,000 |
BOEHRINGER INGELHEIM PHARMACEUTICALS | Boehringer Ingelheim | pharmaceuticals | aviation safety violation | 2014 | FAA | $15,000 |
Boehringer Ingelheim | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2012 | LA-AG | $3,250,000 |
Boehringer Ingelheim Corp. | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2005 | TX-AG | $10,000,000 |
Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2010 | WI-AG | $7,750,000 |
Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Roxane, Inc., Roxane Laboratories, Inc. and Ben Venue Laboratories, Inc. | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2009 | KY-AG | $4,500,000 |
Boehringer Ingleheim | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2011 | KS-AG | $1,400,000 |
Boehringer Ingelheim Animal Health USA Inc. | Boehringer Ingelheim | pharmaceuticals | employment discrimination | 2020 | OFCCP | $379,089 |
Biogen Idec Inc. | Biogen | pharmaceuticals | consumer protection violation | 2007 | VT-AG | $10,000 |
Biogen, Inc. | Biogen | pharmaceuticals | False Claims Act and related | 2020 | DOJ_CIVIL | $22,000,000 |
BIOGEN IDEC, INC. | Biogen | pharmaceuticals | workplace safety or health violation | 2014 | OSHA | $7,500 |
Biocryst Pharmaceuticals, Inc. | Biocryst Pharmaceuticals | pharmaceuticals | hazardous waste violation | 2014 | AL-ENV | $11,000 |
ICN Pharmaceuticals, Inc | Bausch Health | pharmaceuticals | economic sanction violation | 2004 | OFAC | $5,500 |
Biovail Corporation | Bausch Health | pharmaceuticals | accounting fraud or deficiencies | 2008 | SEC | $10,000,000 |
ICN Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | accounting fraud or deficiencies | 2002 | SEC | $1,000,000 |
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. | Bausch Health | pharmaceuticals | benefit plan administrator violation | 2016 | EBSA | $10,001 |
BIOVAIL AMERICAS CORP. | Bausch Health | pharmaceuticals | benefit plan administrator violation | 2012 | EBSA | $10,001 |
ICN Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | fraud | 2001 | USAO | $5,600,000 |
Bausch & Lomb | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $17,500,000 |
Biovail | Bausch Health | pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $200,000 |
Valeant Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | insurance violation | 2018 | CA-INS | $1,875,000 |
Bausch & Lomb Inc. | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | private lawsuit-federal | $10,000,000 |
Medicis Pharmaceutical Corp. | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $23,000,000 |
Valeant Pharmaceuticals International, Inc. | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $23,000,000 |
Valeant Pharmaceuticals International, Inc. | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $11,750,000 |
BAUSCH AND LOMB PHARMACEUTICALS, INC. | Bausch Health | pharmaceuticals | workplace safety or health violation | 2000 | OSHA | $7,000 |
AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2015 | DOJ_CIVIL | $46,500,000 |
AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $2,600,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
AstraZeneca PLC | AstraZeneca | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $5,522,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | False Claims Act and related | 2004 | FL-AG | $807,826 |
AstraZeneca | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | KY-AG | $5,500,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | consumer protection violation | 2010 | KY-AG | $5,391,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | KY-AG | $14,700,000 |
AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $46,500,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,900,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,600,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
AstraZeneca Pharmaceuticals LP and AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2011 | ID-AG | $2,500,000 |
AstraZeneca Pharmaceuticals, LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2010 | HI-AG | $3,333,333 |
AstraZeneca | AstraZeneca | pharmaceuticals | employment discrimination | 2021 | OFCCP | $560,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2007 | private lawsuit-federal | $24,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $11,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | private lawsuit-federal | $20,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $13,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $90,000,000 |
ALEXION PHARMACEUTICALS, INC. | AstraZeneca | pharmaceuticals | workplace safety or health violation | 2012 | OSHA | $8,213 |
MEDIMMUNE DISTRIBUTION LLC | AstraZeneca | pharmaceuticals | environmental violation | 2005 | EPA | $21,125 |
ASTRAZENECA PLP | AstraZeneca | pharmaceuticals | environmental violation | 2021 | EPA | $18,960 |
Astellas Pharma US Inc. | Astellas Pharma | pharmaceuticals | False Claims Act and related | 2019 | DOJ_CIVIL | $100,000,000 |
Astellas | Astellas Pharma | pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $1,130,000 |
OSI Pharmaceuticals LLC | Astellas Pharma | pharmaceuticals | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,200,000 |
Astellas Pharma US, Inc. | Astellas Pharma | pharmaceuticals | campaign finance violation | 2022 | FEC | $7,500 |
Astellas Pharma US, Inc. | Astellas Pharma | pharmaceuticals | price-fixing or anti-competitive practices | 2016 | private lawsuit-federal | $13,250,000 |
Fujisawa Healthcare, Inc. | Astellas Pharma | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $9,615,384 |
Apotex | Apotex Corp. | pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $4,000,000 |
Apotex Corp. | Apotex Corp. | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $24,100,000 |